Why J&J Is Buying Actelion for $30 Billion

The video discusses the discrepancy between Octillion's offer price and current share price, highlighting the impact of Trump's policies on overseas cash use. It explores Johnson & Johnson's strategic acquisition to address revenue shortfalls due to Remicade's vulnerability to biosimilar competition. The discussion also covers the high valuation of the deal amidst potential drug price negotiations and market dynamics.

In what way does the potential competition from biosimilars affect Johnson and Johnson's strategy?

What does the text suggest about the valuation of the deal in light of possible drug price negotiations?